



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 24, 2004 Signature: 
(Jeffrey S. Sharp)

1623 \$
Docket No.: 28053/37955
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ian L. BROWN et al.

Application No.: 10/009,023

Filed: April 12, 2002

Art Unit: 1623

For: STARCH SUB-TYPES
AND LIPID METABOLISM

Examiner: Leigh C. Maier

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each reference on FORM PTO 1449 is attached. A concise explanation of relevance of the items listed on FORM PTO 1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
312-474-6300

By:


Jeffrey S. Sharp
Registration No. 31,879
Attorney for Applicants

February 24, 2004

723590

O 1
FEB 26 2004
C109
BUREAU
TRADEMAKES
OFFICE

SHEET 1 of 1

Form PTO-19 (Modified)

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Atty. Docket No. 28053/37955	Serial No. 10/009,023
Applicant(s) Ian L. Brown et al.	
Filing Date April 12, 2002	1623

RECEIVED
MAR 09 2004

OTHER DOCUMENTS

C07	Intellectual Property Office of New Zealand Examination Report corresponding to New Zealand Patent Application Serial No. 521416, dated 6 May 2003, 2 pages.
C08	Ou S. et al., <i>Journal of Agricultural and Food Chemistry</i> , Feb;49(2): 1026-9 (2001).
C09	Clarke S.D., <i>British Journal of Nutrition</i> , 83 Suppl. 1:59-66 (2000).
C10	Skrabanja V. et al., <i>Journal of Agricultural and Food Chemistry</i> , Jan;49(1):490-6(2001).
C11	Liljeberg H.G. et al., <i>American Journal of Clinical Nutrition</i> 69(4):647-55.
C12	Achour L. et al., <i>American Journal of Clinical Nutrition</i> 66(5):1151-9.

EXAMINER:

DATE CONSIDERED: